Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros
The latest drug development news and highlights from our FDA Performance Tracker
You may also be interested in...
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
Advisory committee votes 10-5 for approval of the monoclonal antibody for prevention of C. difficile recurrence; drug shows 10% absolute reduction in recurrence vs. placebo.